Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S W Tan

Showing results (211-220 of 352) with videos related to

Pageof 36
Sort By:
The Lancet. Oncology|August 12, 2016
Novel therapeutic targets on the horizon for lung cancerWan-Ling Tan, Amit Jain, Angela Takano, et al.
Cell Death & Disease|June 27, 2014
Validation of a chloroquine-induced cell death mechanism for clinical use against malariaJ-H Ch'ng, Y-Q Lee, S Y Gun, et al.
The Journal of Thoracic and Cardiovascular Surgery|September 21, 2025
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancerDavid R Jones, Isabelle Opitz, David Harpole, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2013
Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumorsL Rhoda Molife, Sarah M Rudman, Salma Alam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with <i>BRAF</i> -mutant Solid TumorsRyan J Sullivan, Jeffrey Weber, Sapna Patel, et al.
European Journal of Cancer (Oxford, England : 1990)|February 23, 2023
Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 studyJürgen Wolf, Edward B Garon, Harry J M Groen, et al.
Msphere|January 24, 2018
Targeted Phenotypic Screening in <i>Plasmodium falciparum</i> and <i>Toxoplasma gondii</i> Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box MoleculesGowtham Subramanian, Meenakshi A Belekar, Anurag Shukla, et al.
ESMO Open|July 22, 2022
Trials without borders-decentralized trials and ensuring access to novel cancer therapies during a global pandemicA C Tan, T J Y Tan, S P L Saw, et al.
Msphere|March 15, 2019
Erratum for Subramanian et al., "Targeted Phenotypic Screening in <i>Plasmodium falciparum</i> and <i>Toxoplasma gondii</i> Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box Molecules"Gowtham Subramanian, Meenakshi A Belekar, Anurag Shukla, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 23, 2007
Effect of plasmodial RESA protein on deformability of human red blood cells harboring Plasmodium falciparumJ P Mills, M Diez-Silva, D J Quinn, et al.
Pageof 36

Showing results (211-220 of 352) with videos related to

Sort By:
Pageof 36
The Lancet. Oncology|August 12, 2016
Novel therapeutic targets on the horizon for lung cancerWan-Ling Tan, Amit Jain, Angela Takano, et al.
Cell Death & Disease|June 27, 2014
Validation of a chloroquine-induced cell death mechanism for clinical use against malariaJ-H Ch'ng, Y-Q Lee, S Y Gun, et al.
The Journal of Thoracic and Cardiovascular Surgery|September 21, 2025
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancerDavid R Jones, Isabelle Opitz, David Harpole, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2013
Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumorsL Rhoda Molife, Sarah M Rudman, Salma Alam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with <i>BRAF</i> -mutant Solid TumorsRyan J Sullivan, Jeffrey Weber, Sapna Patel, et al.
European Journal of Cancer (Oxford, England : 1990)|February 23, 2023
Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 studyJürgen Wolf, Edward B Garon, Harry J M Groen, et al.
Msphere|January 24, 2018
Targeted Phenotypic Screening in <i>Plasmodium falciparum</i> and <i>Toxoplasma gondii</i> Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box MoleculesGowtham Subramanian, Meenakshi A Belekar, Anurag Shukla, et al.
ESMO Open|July 22, 2022
Trials without borders-decentralized trials and ensuring access to novel cancer therapies during a global pandemicA C Tan, T J Y Tan, S P L Saw, et al.
Msphere|March 15, 2019
Erratum for Subramanian et al., "Targeted Phenotypic Screening in <i>Plasmodium falciparum</i> and <i>Toxoplasma gondii</i> Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box Molecules"Gowtham Subramanian, Meenakshi A Belekar, Anurag Shukla, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 23, 2007
Effect of plasmodial RESA protein on deformability of human red blood cells harboring Plasmodium falciparumJ P Mills, M Diez-Silva, D J Quinn, et al.
Pageof 36